Read More

Immuron Said Deprioritizing SARS-CoV-2 Research to Focus on Clinical Development of More Advanced Stage Therapeutic Drug Candidates

Immuron Limited (ASX: IMC; NASDAQ: IMRN), a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform for prevention and treatment of gut-mediated diseases; today announced that it has deprioritized SARS-CoV-2 research to focus on the clinical development of our more advanced stage therapeutic drug candidates.

IMRN